Baker Julian's Form 4 filing
TScan Therapeutics, Inc. (TCRX) · filed May 12, 2022
- Accession no.
- 0001209191-22-028579
- Filed
- May 12, 2022, 4:41 PM ET
- Trade date
- May 10-11, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions and 0 derivative transactions. Open-market purchases total $2.56M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baker JulianCIK 0001087939 | Director, 10% Owner |
| Baker FelixCIK 0001087940 | Director, 10% Owner |
| Baker Bros. Advisors LPCIK 0001263508 | Director, 10% Owner |
| Baker Brothers Life Sciences LPCIK 0001363364 | Director, 10% Owner |
| 667, L.P.CIK 0001551139 | Director, 10% Owner |
| Baker Bros. Advisors (GP) LLCCIK 0001580575 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 10, 2022 | Common Stock | PPurchaseAcquired | +40,800 | $1.70 | +$69,360 | 145,498 | Indirect | |
| May 10, 2022 | Common Stock | PPurchaseAcquired | +325,373 | $1.70 | +$553,134.1 | 1,645,675 | Indirect | |
| May 10, 2022 | Common Stock | PPurchaseAcquired | +12,769 | $1.93 | +$24,697.8 | 158,267 | Indirect | |
| May 10, 2022 | Common Stock | PPurchaseAcquired | +101,831 | $1.93 | +$196,961.52 | 1,747,506 | Indirect | |
| May 10, 2022 | Common Stock | PPurchaseAcquired | +95,060 | $1.95 | +$185,367 | 253,327 | Indirect | |
| May 10, 2022 | Common Stock | PPurchaseAcquired | +758,094 | $1.95 | +$1,478,283.3 | 2,505,600 | Indirect | |
| May 11, 2022 | Common Stock | PPurchaseAcquired | +2,882 | $1.99 | +$5,721.63 | 256,209 | Indirect | |
| May 11, 2022 | Common Stock | PPurchaseAcquired | +22,983 | $1.99 | +$45,628.15 | 2,528,583 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.